Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 2,507,092
- Total 13F value
- $8,574,256
- Share change
- +1,853,803
- SEC-reported price per share
- $3.42
- Number of holders
- 2
- Value change
- +$6,340,007
- Number of buys
- 2
- Shares outstanding
- 94,372,096
Holder snapshot
5 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
2
Top holders
2
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Deep Track Capital, LP
Disclosed value leader
Deep Track Capital, LP
Comparable rows
15/15
Latest evidence
12 Aug 2025
13D/G
13F
3/4/5
Lead comparable stake: 10%
13D/G row: Deep Track Capital, LP
Showing 1-6 of 15 holder rows.
Quick read
Deep Track Capital, LP leads the comparable SEC ownership view at 10%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Deep Track Capital, LP's linked filing trail.
Comparable ownership
Top 5
Deep Track Capital, LP
10%
VANGUARD GROUP INC
4.8%
ORBIMED ADVISORS LLC
1.7%
Mark Baldry
0.03%
Natasha Fay Thoren
0.01%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Deep Track Capital, LP |
13D/G
|
10%
|
$4,568,300
2,366,995 shares
|
$0 | 12 Aug 2025 |
| VANGUARD GROUP INC |
13D/G
13F
The Vanguard Group · Company
|
4.8%
|
$1,558,172
8,200,903 shares
|
$0 | 31 Dec 2024 |
| ORBIMED ADVISORS LLC |
13D/G
|
1.7%
|
$25,640
134,947 shares
|
$0 | 30 Jun 2025 |
| Mark Baldry |
3/4/5
Chief Commercial Officer
|
0.03%
|
$62,886
25,337 shares
|
— | 16 May 2025 |
| Natasha Fay Thoren |
3/4/5
Chief Legal Officer
|
0.01%
|
$1,797
9,462 shares
|
— | 20 May 2025 |
| Keith Woods |
3/4/5
Director
|
0.01%
|
$1,140
6,000 shares
|
— | 09 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
2
Shares
2,507,092
Rows available
2
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q4 2025 Across Filers
Q4 2025 holders
3
Q3 2025 holders
2
Holder diff
-1
| Investor | Q4 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q4 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend